Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary



Status:Recruiting
Conditions:Chronic Obstructive Pulmonary Disease, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:50 - 75
Updated:4/13/2015
Start Date:May 2009
Contact:R. Graham Barr, MD, DrPh
Email:rgb9@columbia.edu
Phone:212 305 4895

Use our guide to learn which trials are right for you!

Pulmonary Vascular Changes in Early Chronic Obstructive Pulmonary (MESA-COPD)

The Multi-Ethnic Study of Atherosclerosis (MESA) - Chronic Obstructive Pulmonary Disease
(COPD) Study aims to characterize the pulmonary vascular changes and their biology in early
COPD using imaging, gene expression profiling and peripheral cellular measures.

Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the US
and will soon replace stroke as the third leading cause.

Translation of promising biological hypotheses of COPD pathogenesis to human populations
that may lead to new therapies is urgently needed. The vascular hypothesis of COPD was
articulated almost 50 years ago. Bench research on endothelial dysfunction in COPD is
evolving rapidly and has shown that acrolein in cigarette smoke causes endothelial apoptosis
and endothelial apoptosis is directly implicated in COPD pathogenesis. Clinical studies on
endothelial dysfunction and vascular changes in COPD are limited.

The proposed study is a cross-sectional study of smokers nested among the MESA-Lung
(AAAA7791) and EMCAP Studies (AAAA6484), which together provide a well-defined cohort of
4,617 participants with prior spirometry and CT measures.

The Multiethnic Study of Atherosclerosis - Chronic Obstructive Pulmonary Disease (MESA COPD
Study) has two main scientific purposes:

1. characterize the pulmonary vascular changes in COPD and their biology, and

2. propose novel pathways for new therapies in COPD.

MESA COPD is a cross-sectional study of smokers nested within the MESA-Lung and EMCAP
cohorts of 325 participants (125 cases with mild, 60 cases with moderate and 40 cases with
severe COPD and 100 controls) who will be phenotyped with magnetic resonance (MR) pulmonary
angiography, pulmonary function testing, full-lung CT scans, serum Vascular Endothelial
Growth Factor (VEGF), cell assays and gene expression profiling. MESA COPD Study will
contribute improving the knowledge of early changes in COPD that may lead to novel
disease-modifying medical therapies and preventative strategies.

Inclusion Criteria:

- age 50-75 years at time of enrollment

- ever smokers (10 or more packyears)

- participation in MESA or EMCAP studies

Exclusion Criteria:

- clinical cardiovascular disease (left congestive heart failure (CHF), valve disease,
coronary artery disease (CAD), stroke, or congenital heart disease),

- asthma, pulmonary embolism or lung disease other than COPD,

- weight > 300 lbs,

- chronic renal insufficiency ([eGFR] < 60 mL/min/1.73 m2),

- cancer,

- atrial fibrillation, and

- contraindications to magnetic resonance imagine (MRI), gadolinium, albuterol or
spirometry testing.
We found this trial at
1
site
116th St and Broadway
New York, New York 10027
(212) 854-1754
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
?
mi
from
New York, NY
Click here to add this to my saved trials